Use of BRCA1 mRNA expression levels to predict survival in breast cancer patients (p) treated with neoadjuvant chemotherapy

Abstract Background: Breast cancer is one of the most common tumors for women worldwide. Thrombospondins (THBSs) are reported to play important roles in various cellular processes and are involved in the occurrence and development of human cancers. However, the expression and prognostic value of THBSs family in breast cancer remain unclear.Methods: In this study, we examined the genes and protein expression levels of THBSs and their prognostic value by synthesizing several mainstream databases, including Oncomine, Human Protein Atlas (HPA), UALCAN, and KM Plotter. We also analyzed THBS interaction networks, genetic alterations, functional enrichment, and drug sensitivity with several publicly accessible databases, including GEPIA, GeneMANIA, STRING, cBioPortal, Metascape and NCI-60 database.Results: The results showed that the mRNA expression levels of THBS1, THBS2, THBS3, and THBS5 in breast cancer tissues were significantly higher than in normal tissues. The mRNA expression levels of THBS4 were different in different subtypes of breast cancer, and the protein expression levels of THBS1, THBS2, and THBS4 in breast cancer tissues were higher than in normal breast tissues. Survival analysis showed that breast cancer patients with high THBS1 gene expression showed worse overall survival (OS), relapse-free survival (RFS), and post-progression survival (PPS), and breast cancer patients with high THBS2 gene expression also showed worse RFS. Conversely, lower THBS3 levels predicted worse RFS, and lower THBS4 levels predicted worse OS, RFS, and distant metastasis-free survival (DMFS). Conclusions: These results suggest that THBSs may be potential biomarkers for breast cancer.

Download Full-text

Differential Gene -Based Predictors of Neoadjuvant Chemotherapy Efficacy in Breast Cancer

10.21203/rs.3.rs-1032152/v1 ◽

2021 ◽

Author(s):

Mei Lu ◽

JieYa Zou ◽

Rong Guo ◽

XiaoJuan Yang ◽

Ji Wang ◽

...

Keyword(s):

Breast Cancer ◽

Neoadjuvant Chemotherapy ◽

Prediction Model ◽

Cancer Patients ◽

Residual Disease ◽

Area Under The Curve ◽

Complete Response ◽

Rna Seq ◽

Breast Cancer Patients ◽

Expression Levels

Abstract Background and objectiveChemotherapy is the most common treatment in breast cancer , and neoadjuvant chemotherapy (NAC) is wildly used because of it’s efficiency and safety. To identify significantly differentially expressed genes and select the most suitable breast cancer patients for neoadjuvant chemotherapy (NAC) before treatment. MethodsWe collected a total of 60 breast cancer patient samples before and after NAC. All the samples were subjected to high-throughput RNA sequencing (RNA-seq). Then , we identified AHNAK, CIDEA, ADIPOQ, and AKAP12 as candidate genes related to tumour chemotherapeutic resistance. Next, we analysed the expression levels of AHNAK, CIDEA, ADIPOQ, and AKAP12 by logistic regression and based on the result, we constructed a predictive model visualized by a nomogram. ResultsThe RNA-seq results show that AHNAK, CIDEA, ADIPOQ and AKAP12 are upregulated in residual disease after NAC (P<0.05), and compared with the pathological complete response (pCR) group, the non-pCR group presented high AHNAK, CIDEA, ADIPOQ and AKAP12 expression levels (P<0.05). Logistic analysis showed that high AHNAK, CIDEA, ADIPOQ and AKAP12 expression levels significantly reduced the pCR rate of NAC for breast cancer (P<0.05). In addition, our prediction model , which included AHNAK, CIDEA, ADIPOQ and AKAP12 , showed a good fitting effect with the H1 test (χ2=6.3967, P=0.4945) and the receiver operating characteristic (ROC) curve (area under the curve (AUC) 0.8249, 95% CI 0.722–0.9271). ConclusionHigh expression of AHNAK, CIDEA, ADIPOQ and AKAP12 indicates poor treatment response in breast cancer patients treated with NAC . The efficacy prediction model based on these results is expected to be a new method to select the optimal population of breast cancer patients for NAC.

Download Full-text

8O_PR MUCIN-1 Protein and Mrna Expression in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy

Annals of Oncology ◽

10.1093/annonc/mds039 ◽

2012 ◽

Vol 23 ◽

pp. ii17 ◽

Cited By ~ 1

Author(s):

B.V. Sinn ◽

G. von Minckwitz ◽

C. Denkert ◽

H. Eidtmann ◽

S. Darb-Esfahani ◽

...

Keyword(s):

Breast Cancer ◽

Neoadjuvant Chemotherapy ◽

Mrna Expression ◽

Cancer Patients ◽

Breast Cancer Patients ◽

Mucin 1

Download Full-text

mRNA expression levels of the biological factors uPAR, uPAR-del4/5, and rab31, displaying prognostic value in breast cancer, are not clinically relevant in advanced ovarian cancer

Biological Chemistry ◽

10.1515/bc.2011.166 ◽

2011 ◽

Vol 392 (11) ◽

Cited By ~ 7

Author(s):

Matthias Kotzsch ◽

Julia Dorn ◽

Kristina Doetzer ◽

Barbara Schmalfeldt ◽

Janna Krol ◽

...

Keyword(s):

Breast Cancer ◽

Ovarian Cancer ◽

Mrna Expression ◽

Cancer Patients ◽

Prognostic Value ◽

Tumor Tissue ◽

Advanced Ovarian Cancer ◽

Biological Factors ◽

Expression Levels ◽

Mrna Expression Levels

Abstract High tumor tissue mRNA expression of the tumor biological factors uPAR, uPAR-del4/5, or rab31 is associated with shorter distant metastasis-free and overall survival in breast cancer patients. To evaluate whether these factors are also clinically relevant in ovarian cancer, we quantified the respective mRNA levels in primary tumor tissue of advanced ovarian cancer patients (n=103) and evaluated their association with clinicopathological parameters and patients’ prognosis. mRNA expression levels of all three markers did not show any significant association with overall or progression-free survival, demonstrating that these factors have no prognostic value in advanced ovarian cancer.

Download Full-text